Cue Pharma Posts Two Responses From CUE-101 Combo In Head & Neck Cancer

Early data from a trial evaluating Cue Biopharma Inc's CUE CUE-101 combined with Merck & Co Inc's MRK Keytruda (pembrolizumab) demonstrated that two out of four patients in dose-escalation cohorts had partial responses.

  • The other two patients are showing reductions in target lesions.
  • CUE-101, which targets IL-2, is under development as a potential third-line treatment for HPV+ recurrent/metastatic head and neck squamous cell carcinoma.
  • CUE-101 + pembrolizumab combination therapy is under examination as a front-line treatment.
  • Updated data on the dose-expansion CUE-101 as a monotherapy trial showed a 50% clinical benefit rate.
  • The Company plans to file an Investigational New Drug (IND) application for CUE-102, another candidate from IL-2 based CUE-100 series, in Q1 of 2022.
  • In January, the Company received a $3 million milestone payment from LG Chem Life Sciences under an agreement for CUE-102.
  • Price Action: CUE shares closed at $10.60 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!